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Background: Idiopathic pulmonary fibrosis (IPF) is a rapid progressive fibro-proliferative disorder with poor prognosis
similar to lung cancer. The pathogenesis of IPF is uncertain, but loss of epithelial cells and fibroblast proliferation are
thought to be central processes. Previous reports have shown that BARD1 expression is upregulated in response to
hypoxia and associated with TGF-β signaling, both recognized factors driving lung fibrosis. Differentially spliced BARD1
isoforms, in particular BARD1β, are oncogenic drivers of proliferation in cancers of various origins. We therefore
hypothesized that BARD1 and/or its isoforms might play a role in lung fibrosis.
Methods: We investigated BARD1 expression as a function of TGF-β in cultured cells, in mice with experimentally
induced lung fibrosis, and in lung biopsies from pulmonary fibrosis patients.
Results: FL BARD1 and BARD1β were upregulated in response to TGF-β in epithelial cells and fibroblasts in vitro and
in vivo. Protein and mRNA expression studies showed very low expression in healthy lung tissues, but upregulated
expression of full length (FL) BARD1 and BARD1β in fibrotic tissues.
Conclusion: Our data suggest that FL BARD1 and BARD1β might be mediators of pleiotropic effects of TGF-β. In
particular BARD1β might be a driver of proliferation and of pulmonary fibrosis pathogenesis and progression and
represent a target for treatment.
Keywords: BARD1, TGF-β, Lung fibrosis, Apoptosis, Proliferation, Differential splicing, Epithelial-mesenchymal
transition (EMT)Introduction
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, pro-
gressive and fatal disease with limited treatment options
[1, 2]. Of the main subtypes of IPF, usual interstitial
pneumonia (UIP) is typically associated with extensive
and persistent lung fibrosis, and non-specific interstitial
pneumonia (NSIP) is associated with inflammation and
fibrosis. The incidence of these diseases is increasing
and is reported to be about 20 per 100,000 [3, 4].
The pathogenesis of IPF is poorly understood, but is
thought to be caused by epithelial damage followed by a
chronic progression of the healing response, resulting in* Correspondence: irmgard.irminger@unige.ch
1Molecular Gynecology and Obstetrics Laboratory, Department of
Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland
2Department of Genetic and Laboratory Medicine, Geneva University
Hospitals, Geneva, Switzerland
Full list of author information is available at the end of the article
© André et al. 2015 Open Access This article
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeexcessive deposition of extracellular matrix proteins
without resolution [5, 6]. Transforming Growth Factor-β
(TGF-β) is generated via multiple molecular pathways
associated with lung fibrosis [1, 7] and is one of a number
of factors known to drive fibrosis. TGF-β signals through
Smad3 to induce collagen production, a hallmark of lung
fibrosis [8, 9]. Many inflammatory cells, central to fibrosis,
store and secrete TGF-β. Coagulation cascade proteins,
such as thrombin, are known to induce TGF-β activation
[10], as does oxidative stress [11]. TGF-β is thought to
drive epithelial cell apoptosis, epithelial-mesenchymal
transition (EMT), fibroblast proliferation, and collagen
deposition, key processes to the initiation and progression
of lung fibrosis.
Currently, there are no molecular biomarkers in wide-
spread clinical use for IPF. Several susceptibility loci have
been identified by genome wide association studies [12],is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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targets as yet.
We hypothesized that BARD1 (BRCA1-associated
RING domain 1), which is aberrantly expressed and cor-
related with poor prognosis in lung cancer [13], might
be involved in lung fibrosis. BARD1 is a major binding
protein of the breast cancer predisposition gene product
BRCA1 and a tumor suppressor in its own right [14].
Bound to BRCA1, BARD1 is essential for BRCA1’s E3
ubiquitin ligase and tumor suppressor activity in DNA
repair and cell cycle control [15]. Independently of
BRCA1, BARD1 is an inducer of apoptosis by binding to
and stabilizing p53 [16–18] and is upregulated in response
to hormones, genotoxic stress, and hypoxia [16, 18–20].
However, BARD1 expression is also upregulated in prolif-
erative tissues [21], where it has essential functions in
mitosis [17, 22, 23]. Thus, there is strong evidence that
BARD1 is involved in apoptosis and in the control of
proliferation.
Alternatively spliced isoforms of BARD1 have been
identified in various cancers correlated with disease pro-
gression and poor prognosis [13, 24–28]. These iso-
forms, abundantly expressed in tumors and cancer cell
lines, lack the BRCA1-interacting N-terminal RING
domain and do not retain tumor suppressor functions.
In particular BARD1β has been shown to be essential for
cell proliferation and for promoting fibroblast proliferation
[23, 25]. BARD1β is considered a driver of tumorigenesis,
as its expression correlates with tumor progression, poor
prognosis, and decreased survival time of lung cancer
patients [13].
The role of BARD1 in the development and progres-
sion of proliferative lung diseases other than cancer
remains unknown. Recent reports suggest that the
pathogenesis of lung cancer and lung fibrosis share com-
mon features [29], and, for example, persistent epithelial
cell damage and enhanced fibroblast proliferation are
observed in both diseases, with IPF patients showing an
8–14 fold increase in lung cancer incidence [30].
Hallmarks of lung fibrosis are thought to be hypoxia,
loss of epithelial cells due to apoptosis and/or EMT, and
fibroblast proliferation [31, 32]. BARD1 was described as
a mediator of stress signals, including hypoxia, towards
apoptosis in vitro and in vivo [16]. BARD1 might also be
linked to TGF-β signaling, as upregulated BARD1
expression was shown along with TGF-β early response
genes in breast cancer [33] and was associated with
endoglin upregulation, a co-receptor for TGF-β [34].
Based on the key properties of BARD1 and its iso-
forms, and the observed features that characterize pul-
monary fibrosis, we hypothesized that full length (FL)
BARD1 and/or its isoforms might play a role in this
disease. To test this hypothesis, we investigated the pos-
sible mechanisms of BARD1 actions by exploring theregulation of FL BARD1 and isoform expression by
TGF-β and by their exogenous overexpression in vitro.
We also analyzed BARD1 expression in lung tissues
from patients with IPF and those of mice following
experimentally induced lung fibrosis.Materials and methods
Clinical data
Human lung biopsies of patients with Idiopathic Intersti-
tial Pneumonias (IIP), IPF and NSIP, and human control
lung tissue samples, were obtained in accordance to an
approved protocol by the Institutional Ethics Commit-
tees of the University Hospitals Geneva (HUG) and the
Hôpital Bichat, Paris. In total, 17 IIP samples and seven
control lung tissue samples were analyzed. Control lung
tissue samples were obtained from resected lung tissue
collected during lung cancer surgery; samples were taken
at sites distal to tumors. Five control samples were
obtained from patients with other lung diseases, which
included emphysema, tuberculosis, and carcinoid dyspla-
sia. All patients were informed and approvals were ob-
tained from the local ethics committees.
Paraffin-embedded sections from human tissue biop-
sies and air-inflated, perfusion-fixed lungs from mice
were immune stained for BARD1 and α-smooth-muscle-
actin (α-SMA). The primary antibodies used in the study
were: BARD1-N19 (sc-7373; Santa Cruz; dilution 1:25)
(BARD1 exon 1); BARD1-C20 (sc-7372; Santa Cruz;
dilution 1:20) (BARD1 exon 11); BARD1-BL (A300-263A;
Bethyl Laboratories; dilution 1:50) (middle exon 4); α-
smooth muscle actin (ab5694; Abcam, dilution 1:100);
BARD1-p25 (directed against sequence of alternative open
reading frame of BARD1β) [23, 25] (dilution 1:50); p53
(sc-6243 Santa Cruz, dilution 1:20); Bax (sc-493; Santa
Cruz; dilution 1:100). Secondary, horseradish-conjugated
rabbit or goat antibodies were used at a 1:100 dilution.
Then diaminobenzidine DAB staining was performed dur-
ing 15 min at room temperature. Slides were counter-
stained with haematoxylin.Mouse model of bleomycin-induced pulmonary fibrosis
C57BL/6J male mice aged 12–16 weeks were kept in
specific pathogen-free conditions. All animal experi-
ments were approved by the Institutional Ethics Com-
mittee of Animal Care in Geneva and the Cantonal
Veterinary Office. Male mice, weighing 20–30 g, were
anesthetized with ketamine/xylazine (i.p., 90/3.8 mg/kg).
Bleomycin or saline was instilled intratracheally at a dose
of 2U/kg to mice using an endotracheal catheter at-
tached to a 50-ml Hamilton syringe (Hamilton Bonaduz)
as previously described [35]. Mice were killed at day 3 or
15 after bleomycin treatment and lungs were processed
for subsequent analysis.
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The normal human fibroblasts CCD-19Lu, bronchial
epithelial cells 16HBE and NuLi-1, alveolar basal epithe-
lial cells A549, and mouse fibroblasts L929 were cul-
tured in RPMI 1640 Medium, GlutaMAX™ (Invitrogen),
10 % fetal calf serum (FCS), 200U/ml penicillin and
200U/ml streptomycin at 37 °C in a 5 % of CO2 incuba-
tor. For TGF-β1 treatment, cells were serum starved in
0.5 % FCS overnight prior to stimulation with 10 ng/ml
recombinant TGF-β1 (Biolegend) for 24 or 48 h. In the
Smad signaling inhibition assay, SB431542 (Abcam) was
added to the media at a concentration of 10 μM 1 h
prior TGF-β1. Following stimulation cell lysates were
prepared for RNA extraction, using Qiagen RNAeasy kit
(Qiagen), for protein extraction or cells were fixed for
immunofluorescence assays. Details are available in the
online supplement.
Statistical analysis
Results are expressed as mean-standard deviation as
indicated and were analyzed with the two-tailed Student’s
t test (GraphPad Prism). Significance level was set at
p < 0.05.
Results
FL BARD1 and BARD1β expression changes in response
to TGF-β
As BARD1 was shown to be induced along with TGF-β
early response genes [33] and to be regulated by the
TGF-β co-receptor endoglin [34], we investigated the
relationship between TGF-β and BARD1 expression
in vitro. We incubated epithelial cells and fibroblasts
with TGF-β and evaluated expression changes of BARD1
and/or its isoforms in response to TGF-β (Fig. 1).
After TGF-β treatment of CCD-19Lu lung fibroblasts,
the expression of FL BARD1, a protein of 95 kD, as well
as BARD1β, 82 kD, was upregulated after 24 and 48 h
(Fig. 1a, b). We also used bronchial epithelial cells
16HBE and NuLi-1 to monitor BARD1 expression after
TGF-β treatment. In these epithelial cells the increase in
BARD1 expression in response to TGF-β was only mod-
erate, and FL BARD1 expression increased, but less so
BARD1β. To investigate whether BARD1 upregulation
in response to TGF-β was observed in other cell lines
we also tested L929 fibroblasts and A549 lung epithelial
cells (Fig. 1c), as well as LL86 and HS888, normal lung
fibroblasts and HeLa and HEK 293, epithelial cells (data
not shown). FL BARD1 and BARD1β were upregulated
in L929 cells with a similar pattern as observed for
CCD-19Lu fibroblasts. The response in A549 cells was
different from 16HBE and NuLI-1 epithelial cells, and a
higher increase of BARD1β expression was observed
(Fig. 1c). All other cell lines showed an increase at 24 h,
but great variability after 48 h. To demonstrate thatBARD1 expression was induced directly by TGF-β, we
used a SMAD inhibitor and monitored BARD1 expres-
sion in response to TGF-β (Fig. 1d). In the presence of
the SMAD inhibitor TGF-β-dependent FL BARD1 and
BARD1β upregulation was reduced to levels without
TGF-β stimulation.
As hypoxia is thought to also act as driver of lung
fibrosis, we investigated whether BARD1 expression was
modified by hypoxia in lung fibrosis. Both FL BARD1
and BARD1β were upregulated in lung epithelial cells
and fibroblasts upon hypoxic treatment (Additional file 1:
Figure S1). Therefore both factors hypoxia and TGF-β are
activators of BARD1 expression.
We have shown previously that BARD1β promotes
cancer cell proliferation and induces proliferation of
non-transformed fibroblasts [23, 25], we wanted to
monitor the specific expression of FL BARD1 and
BARD1β in response to TGF-β treatment. We probed
Western blots of A549 and L929 cells cultured in the ab-
sence or presence of TGF-β for expression of FL BARD1
and BARD1β using an antibody specifically recognizing
the N-terminal region of BARD1β, P25 [23, 25] (Fig. 2a).
A549 cells and L929, both showed an increase of FL
BARD1 expression, as well as an upregulation of
BARD1β after treatment with TGF-β. The increase of FL
BARD1 and BARD1β expression in A549 cells was ac-
companied by an increase of α-smooth muscle actin and
fibronectin, as well as the decrease of E-cadherin, con-
sistent with the well-described function of TGF-β as
EMT inducer [36, 37] (Fig. 2b).
We performed immunofluorescence microscopy to as-
sess the subcellular distribution of BARD1 upon TGF-β
treatment. We observed that BARD1 expression and
localization changed in parallel to changes in expression
of markers of EMT (Fig. 2c). In non-treated cells, although
under starving conditions, E-cadherin was observed
both at the cell-cell adhesion sites and close to the nuclear
membrane. Fibronectin showed nuclear and cytoplasmic
localization. BARD1 expression was observed mostly in the
nucleus and less in the cytoplasm, and not at cell adhesion
sites. In TGF-β treated cells, E-cadherin staining was lost at
cell adhesion sites and appeared diffuse in the nucleus and
cytoplasm and intense staining was observed in the nucleus
in approximately 10 percent of cells. Fibronectin expression
was increased with TGF-β treatment and localized to the
nuclear membrane and to vesicles at the cell membrane,
presumably cell adhesion points. As observed on Western
blots, BARD1 staining was generally stronger in the TGF-β
treated cells and localized to the nucleus and cytoplasm
(Fig. 2c). Specifically elevated BARD1 expression was
observed in dots at the cell membrane, as observed for
fibronectin staining. Double labeling for fibronectin and
BARD1 showed co-localization in the cytoplasm and in
particular in the presumed cell adhesion points (Fig. 2d).
Fig. 1 TGF-β modulates BARD1 expression. Human lung fibroblasts (CCD-19Lu), bronchial epithelial cells (16HBE, NuLi-1), alveolar basal epithelial
cells (A549), and mouse fibroblasts (L929) were cultured in absence (NT) or presence of TGF-β1 (10 ng/ml), and cell extracts were prepared after
24, and 48 h of treatment. a Western Blots of CCD-19Lu, 16HBE and NuLi-1 cell extracts prepared at 24 and 48 h of TGF-β treatment, probed with
anti-BARD1 BL (mapping exon 4 of BARD1) antibody recognizing FL BARD1 and BARD1β. b CCD19-Lu and 16HBE and (c) A549 and L929 Western
Blots were quantified by measuring spot density using AlphaEaseFc software. Each bar represents mean + SD (n ≥2 experiments); two-tailed Student’s
T-Test *p < 0.05, TGF-β1 versus non-treated. d A549 culture in presence of SB-431542 1 h prior TGF-β1 treatment. Cell extracts were prepared after 48 h
of TGF-β1/SB-431542 treatment and probed with anti-BARD1 BL, anti-Smad2/3, anti-pSmad antibodies
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to fibronectin upregulation and E-cadherin repression, both
features of EMT, suggested that BARD1 played a role in
this pathway. To determine whether FL BARD1 or
BARD1β play a role in TGF-β-mediated EMT induction,
we exogenously expressed FL BARD1 or BARD1β in A549
cells and monitored their expression, and the effect thereof
on fibronectin and E-cadherin expression and localization.Western blots and RT-PCR of cell extracts showed
that fibronectin was upregulated in BARD1β overex-
pressing cells, as compared to FL BARD1 expressing or
non-transfected cells (Fig. 3a, b), while no changes were
observed for E-cadherin expression (data not shown).
These findings might suggest that BARD1β affects
fibronectin accumulation and cytoplasmic localization
in A549 cells.
Fig. 2 (See legend on next page.)
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Fig. 2 TGF-β induces BARD1β overexpression and localization. a Schematic representation of cDNA structure of FL BARD1 and N-terminally truncated
isoform BARD1β. Approximate locations of protein motifs RING finger (RING), ankyrin repeats (ANK), and BRCT domains (BRCT) of BARD1 are indicated.
Green exons indicate protein coding open reading frame (ORF). BARD1β encodes an alternative ORF in the first exon. Arrows indicated approximate
positions of epitopes reactive with the antibodies used. b Lung epithelial cells (A549) and fibroblasts (L929) were cultured in absence (NT) or presence
of TGF-β1, and cell extracts were prepared after 24 and 48 h. Western blots of cell extracts were probed with anti-BARD1 BL (exon 4), BARD1β-specific
P25 (alternative ORF of BARD1β), α-SMA, E-cadherin, fibronectin, and β-actin antibodies. c A549 were treated with TGF-β1 and cells were fixed after
48 h. Immunofluoresence was performed with anti-E-cadherin, fibronectin, or BARD1 BL (exon 4) antibodies. d Co-immunostaining with anti-BARD1 BL
and fibronectin (Fib) antibodies. TGF-β1 modulates BARD1 localization to areas at the cell membrane (yellow arrows) and cytoplasmic vesicles (white arrows),
similar to and co-staining with fibronectin. Scale bars 20 μm
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pression of BARD1β induced increased proliferation of
A459 lung epithelial cells, which was not observed with
FL BARD1 expressing cells or controls (Fig. 3c). Overex-
pression of FL BARD1 and BARD1β in the fibroblast cell
line L929 showed an even more pronounced increase of
proliferation for BARD1β, but proliferation arrest for FL
BARD1 (Fig. 3d).
As FL BARD1 was known as a mediator of apoptosis
[16–18], we tested whether FL BARD1 induced apoptosis
in A549 and L929 cells, and to what extent. We stained
control cells and FL BARD1 or BARD1β overexpressing
cells for annexin v and analysed them by FACS (Fig. 3e-g).
Only FL BARD1, but not BARD1β significantly induced
apoptosis in both cell lines.
Together these results suggest that FL BARD1 and
BARD1β can be upregulated by TGF-β, and increased
BARD1β might promote cell proliferation and act in a
pathway regulating stability and/or intracellular localization
of fibronectin. FL BARD1 upregulation leads to increased
apoptosis of epithelial cells and fibroblasts.
BARD1 expression is upregulated in mouse model of lung
fibrosis
Despite its limitations, several key features of human
lung fibrosis are reproduced in the mouse model of lung
fibrosis following administration of bleomycin [38].
These features include epithelial cell apoptosis and fibro-
blast proliferation and differentiation. We thus investi-
gated whether BARD1 expression in lung tissues from
mice with bleomycin induced lung fibrosis reflected the
expression pattern observed in vitro and whether it par-
alleled the progression of the disease in this model.
Importantly, this model permits to investigate BARD1
expression at early stages of the disease.
We investigated FL BARD1 and/or BARD1 isoform
expression on the mRNA level by RT-PCR and deter-
mined which forms of BARD1 were expressed in lung tis-
sues from bleomycin-treated and control mice (Fig. 4a, b).
FL BARD1, BARD1β, and BARD1ε mRNA levels were the
most abundant isoforms and BARD1β was significantly in-
creased in the lungs of bleomycin-treated mice. To evalu-
ate the overall extent of fibrosis, collagen deposition was
measured in parallel using the sircol assay (Fig. 4c) and bymeasuring collagen type 1 alpha 1 levels by real time PCR
(not shown). Real time PCR was similarly performed for
expression of RNAs transcribed from exon 4 of BARD1
(Fig. 4d). To determine the expression of individual BARD1
isoforms we performed semi-quantitative PCR (Fig. 4e).
The increase of BARD1βmRNA expression was statistically
significant, but expression changes for FL BARD1 or other
isoforms were not, with the exception of a significant
down-regulation of BARD1ε. Whether BARD1ε plays a
role, as protein or mRNA, in preventing lung fibrosis re-
mains to be determined.
To analyze overall BARD1 expression in the mouse
model of lung fibrosis, BARD1 C20 antibody recognizing
a C-terminal epitope common to all isoforms was used.
While only weak expression was seen in lung tissues of
control mice, BARD1 expression was upregulated in
lung tissues from bleomycin-treated mice (Fig. 5a).
BARD1 expression was first observed in epithelial cells
at 3 days following bleomycin treatment. At 15 days
after treatment, the epithelium remained strongly posi-
tive, and fibroblasts in fibrotic regions also showed
BARD1 expression, in both the nucleus and cytoplasm.
To distinguish different forms of BARD1, we used anti-
body N19, specific for epitopes present in FL BARD1
and absent in BARD1β, which showed a faint dotted
staining in cells in the fibrotic regions (Fig. 5b). The ex-
pression of epitopes present in FL BARD1 and BARD1β,
recognized by antibody BL, was stronger and observed
in most cells, presumably fibroblasts. The BARD1β-specific
antibody P25 showed a similar staining as BL, suggesting
that the staining observed with antibody BL mostly repre-
sents BARD1β staining (Fig. 5b).
These data show that BARD1 expression is modulated
in the bleomycin model of lung fibrosis, and specifically
BARD1β is upregulated in cells within fibrotic regions at
15 days post treatment.
BARD1 expression is associated with apoptosis
As FL BARD1 mediates apoptosis by binding to and
stabilizing p53, and BARD1-repressed cells are resistant
to apoptosis [16], and apoptosis of epithelial cells is
thought to be one of the mechanisms leading to epithe-
lial cell loss in fibrosis, we investigated FL BARD1
expression and its association with apoptosis markers in
Fig. 3 Differential effect of FL BARD1 and BARD1β on cell proliferation and apoptosis. a-b A549 cells were transfected with FL BARD1 and BARD1β
expressing plasmids and cell extracts were prepared after 48 h. a Western Blots probed with anti-BARD1 (BL) and fibronectin. b RT-PCR
analysis performed with primers for amplification of full length (FL) BARD1 (exon 1 to exon 11) or isoform BARD1β using primers from
exon 1/4 junction and exon 11. c A549 and (d) L929 cell proliferation of control transformed cells (pcDNA), and cells expressing exogenous FL BARD1
or BARD1β was monitored over 3 days. BARD1β leads to increased proliferation, as described before. e Annexin V and PI staining of (e, f)
A549 and (e, g) L929 24 h after transfection with FL BARD1, BARD1β or pcDNA control expressing plasmids. FL BARD1 induced cell apoptosis. Each bar
represents mean + SD (n ≥2 experiments); two-tailed Student’s T-Test *p < 0.05, BARD1 versus control
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observed that BARD1 staining in fibrotic regions co-
incided with the expression of proteins implicated in
the BARD1-induced apoptosis pathway [16], namely
p53 and Bax, (Fig. 5c). BARD1, p53, and the p53–induced pro-apoptotic protein Bax showed prominent
staining in the epithelium adjacent to fibrotic areas
that also stained for BARD1. These data are consist-
ent with the previously described role of FL BARD1
in apoptosis [16–18].
Fig. 4 RNA expression pattern of BARD1 mRNA isoforms in bleomycin induced lung fibrosis. a Exon structures of mRNAs of FL BARD1 and isoforms
are aligned. Locations of protein motifs are indicated as in Fig. 2a. Greek names of isoforms are indicated on the left and size in bp on the right. Exons
with open reading frames (ORF) are marked as green, non-coding as white, alternative ORFs as yellow. Arrows indicate position of forward (For) and
reversed (Rev) primers used for RT-PCR. b RT-PCR on lung tissues from control (Saline) and Bleomycin (Bleo)-treated mice at 15 days after treatment is
shown, performed with primers amplifying exon 1 to 11 or the region from exon 1/4 junction (BARD1β-specific) to exon 11 (ex1/4- ex11). Amplicons
of BARD1 isoforms are indicated with Greek letters. GAPDH was amplified as RNA quantity and quality control. c Collagen expression was determined
by Sircol assay at 15 days after bleomycin treatment. d Quantitative PCR analysis at 15 days after bleomycin assay showed a significant increase of BARD1
expression. e Semi-quantitative RT-PCR analysis at 15 days after bleomycin treatment of FL BARD1, BARD1β, BARD1φ, and BARD1ε mRNA expression
showed a significant increase of BARD1β expression and a highly significant decrease of BARD1ε. Each bar represents mean + SD (n ≥6 mice in each
group); Student’s T-Test *p < 0.05, **p < 0.01, ***p < 0.005 Bleo- versus saline-treated
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lung fibrosis
To evaluate the association of BARD1 with human lung
fibrosis, we investigated its expression in lung biopsies
from patients with pulmonary fibrosis (Fig. 6).
To determine the specific expression of FL BARD1
and/or BARD1 isoforms on the mRNA level, we per-
formed RT-PCR on RNA extracted from lung biopsies
from patients with pulmonary fibrosis (n = 17) and con-
trols (Fig. 6a). Amplification of the entire BARD1 coding
region (exon 1 to exon 11) showed no or very low
expression of previously identified BARD1 isoforms in
healthy tissues, but expression of FL BARD1 and BARD1β,as well as low expression levels of smaller isoforms was
detected in IPF tissue samples (Fig. 6a). Using a BARD1β
specific primer, we confirmed that BARD1β mRNA was
the most frequently expressed in IPF samples.
We then performed IHC with antibody C20 recogniz-
ing a C-terminal epitope of BARD1 on tissue samples of
NSIP as well as UIP patients. C20 showed BARD1 ex-
pression in NSIP and UIP, while only weak staining was
observed in control tissues (Fig. 6b). BARD1 expression
specifically localized to the fibrotic regions and was ob-
served in all patients tested. The number of positive cells
appeared to increase with progression of the fibrotic le-
sions, while minimal staining was observed in unaffected
Fig. 5 BARD1 epitopes differential expression and its association with apoptosis in in bleomycin-induced lung fibrosis in mice. a IHC of lung tissue
of mice with bleomycin-induced lung fibrosis at 3 and 15 days after treatment (Bleo) and controls (Saline) using anti-BARD1 antibody (C20) directed
against the BARD1 C-terminus. b IHC with antibodies against the N-terminal (N19) or middle region (BL) of BARD1, or the alternative ORF in exon 1
(P25) in saline or bleomycin-treated mice at 15 days after treatment. All antibodies show an increase of staining after bleomycin treatment. While N19
shows a dotted staining mostly in epithelial cells of alveolar walls, BL shows a strong staining of most cells both in alveolar area and dense fibrotic area
15 days after treatment. P25 staining, specific for BARD1β, is cytoplasmic and at the membrane of epithelial cells. c IHC on adjacent tissue sections
using BARD1 N-terminal (N19), p53 and Bax antibodies is shown for dense fibrotic lung tissue. BARD1 is co-expressed with components
of the BARD1-apoptosis pathway, p53 and Bax. Scale bars 20 μm
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the spliced isoform BARD1β are expressed in fibrotic lung
tissues and are associated with the disease.
IHC with antibodies directed against different epitopes
of the FL BARD1 protein, namely N19 recognizing FL
BARD1 and possibly small isoforms (Fig. 4a) and BL rec-
ognizing FL and BARD1β, showed that different epitopes
of BARD1, reflecting different isoforms, were expressed
in different regions: N19 detecting mainly FL BARD1
was highly expressed within the hyperplastic epithelium,
but less in areas with collagen depositions and fibroblasts,
as shown for NSIP and UIP (Fig. 7a, b). BARD1 BLstaining, similar to P25 staining (Fig. 5b) and reflecting ex-
pression of BARD1β, was mostly observed in cells within fi-
brotic regions and coincided with α-smooth muscle actin
staining. The same regions were less stained by N19, sug-
gesting that isoform BARD1β and not FL BARD1 was
expressed in fibrotic regions and presumably in fibroblasts.
Discussion
We report here for the first time that the tumor suppres-
sor BARD1 and its pro-proliferative isoform BARD1β are
associated with pulmonary fibrosis and presumably in-
volved in its pathogenesis.
Fig. 6 BARD1 expression is associated with human lung fibrosis. a RT-PCR with primers amplifying exon 1 to exon 11 (ex1- ex11) on tissues from
control (non-symptomatic individuals) and a selection of IPF patients (total n= 17) is shown, performed with primers amplifying exon 1 to 11 or the region
from exon 1/4 junction (BARD1β-specific) to exon 11 (ex1/4- ex11). Amplicons of BARD1 isoforms are indicated with Greek letters. GAPDH was amplified as
control for RNA quality and quantity. In control lung tissues, only BARD1γ, BARD1δ, and BARD1η were detected, but no FL BARD1 or BARD1β. In tissues
from fibrosis patients FL BARD1 and BARD1β were amplified in 70 percent of the samples. b Immunohistochemistry with anti-BARD1 antibody C20 shows
representative cases of healthy lung tissue and tissues from patients with NSIP and UIP. Thickening interstitial areas and fibroblastic foci stained strongly for
BARD1. Scale bars 100 μm
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for lung fibrosis
Several proteins, including NADPH oxidase 4, Toll-like
receptor 3, CCL18, matrix metalloproteinase-7, and
interleukin-8, besides TGF-β, are widely accepted as key
players in pulmonary fibrosis [39]. In recent years sev-
eral genes were identified that are critically involved in
the pathogenesis of lung fibrosis [12, 40]. Some of the
newly identified genes are involved in hitherto ignored
pathways, namely cell-cell adhesion, host defense, and
DNA repair [12].
The BARD1 gene was not discovered as one associated
with lung fibrosis in previously reported genetic screens.
This could be due to the switching of the splicing pat-
tern of the BARD1 gene that is associated with lung
fibrosis, which would need other approaches for detec-
tion than screening for mutations or overall expression
changes. Indeed there is evidence that SNPs in BARD1
that are associated with a subgroup of high-risk, aggres-
sive, neuroblastoma, promote alternative splicing and
expression of BARD1β [25, 41]. Exon and intron sequen-
cing of the BARD1 gene has identified mutations in
exons and introns that affect splicing in breast andovarian cancer [42]. It is therefore possible that SNPs in
BARD1 might be found associated with specific sub-
classes of lung fibrosis.
We hypothesized that the tumor suppressor BARD1,
with functions in DNA repair pathways, plays a role in
the pathogenesis of lung fibrosis, as previous reports
suggested a role of BARD1 in the regulation of prolifera-
tion: i) BARD1 expression is upregulated in proliferating
cells, ii) BARD1 isoforms are highly upregulated in can-
cer cells, and associated with uncontrolled or deregu-
lated growth. As uncontrolled growth is also the feature
of lung fibrosis, BARD1 expression was expected to be
associated with lung fibrosis.
Distinct expression patterns of BARD1 and its isoforms in
lung fibrosis and cancer
The pro-proliferative functions of isoform BARD1β were
first described in in vitro cultures of epithelial cells [23]
and confirmed in non-transformed fibroblasts [25]. Con-
sistent with its pro-proliferative action BARD1β was
found expressed in most epithelial cell-derived cancers,
but in combination with other isoforms and absence of
FL BARD1 [13, 24, 26, 28]. In fibrotic lung tissues, the
Fig. 7 Differential expression of BARD1 epitopes in human lung fibrosis. a IHC of tissues of NSIP patients performed with anti-BARD1 N19 (a-c)
and BL (d-f) antibodies. Adjacent tissue sections were also stained for α-SMA (g-i). Myofibroblast are preferentially stained by BL antibody and co-localized
with α-SMA staining (arrows) in foci of loose proliferation of interstitial smooth muscle cells, as interstitial smooth muscle cells may be seen in the fibrosis
pattern of NSIP. b IHC of tissues from IPF/UIP patients stained with anti-BARD1 N19 (a-c) and BL (d-f), and α-SMA (g-i) antibodies. Thickening interstitial
areas stained strongly with N19 (arrow heads) (b, c). Regions that stained for α-SMA also were preferentially stained by BL (arrows)
(e, f, h, i), suggesting co-expression of BARD1β and α-SMA in fibroblastic foci
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and BARD1β. This difference is striking and might
reflect the less complex nature of the cells forming the
fibrotic tissue. Cancer cells have the capacity to evade
apoptosis, grow independently of growth signals, haveactivated telomerase and unlimited growth, escape im-
mune surveillance, and become invasive and metastatic
[43]. Compared to these changes the proliferating fibro-
blasts have acquired only little cancer cell-like capacities.
The activation of telomerase might be associated with
André et al. Respiratory Research  (2015) 16:118 Page 12 of 14lung fibrosis [44]. Fibrotic fibroblasts and epithelial cells
express FL BARD1 and BARD1β. Loss of FL BARD1
leads to genetic instability, a hallmark of cancer cells,
but not so much of lung fibrosis.
A role of TGF-β in up-regulating FL BARD1 and its
isoforms
Knowing what causes FL BARD1 and BARD1β upregu-
lation in fibrotic tissues may help us resolve whether the
particular expression pattern is cause or consequence of
the fibrotic transformation of lung tissue. Our data
suggest that BARD1 and BARD1β are downstream of
TGF-β in exerting effects on epithelial cells and fibroblasts
(Fig. 8). Several reports have linked BARD1 expression to
TGF-β-dependent pathways [33, 34]. Indeed, of the large
number of transcription factors that specifically bind to
the BARD1 promoter [45], several are activated in a
TGF-β pathway (Additional file 1: Table S1), consistent
with our finding that BARD1 expression can be regulated
by TGF-β.
The data presented here confirm that TGF-β induces
BARD1 expression and demonstrate for the first time
that this occurs in lung fibrosis. Specifically, we observe
upregulation of BARD1β on the mRNA and protein level
in epithelial cells and fibroblasts. The upregulation of
BARD1β in fibroblasts is consistent with the view that
BARD1β acts as a pro-proliferative factor in a TGF-β
pathway in lung fibrosis. Importantly, upregulation is
cell type specific with marked differences between epi-
thelial cells and fibroblasts. One explanation of these dif-
ferences could be the differential expression of TGF-β
receptors on epithelial cells and fibroblasts. It is also
possible that other regulatory pathways are involved,
such as microRNAs (miRNAs). Several miRNAs are
implicated in TGF-β signaling, as recently reported for
lung cancer [46]. The BARD1 3’UTR is target of a large
number of miRNAs, including those induced by TGF-β
signaling, that regulate the pattern of BARD1 isoform
expression [45]. Further studies are required to unravel
miRNA-mediated regulation of the TGF-β-dependent
BARD1 expression.Fig. 8 Signaling from TGF-β towards FL BARD1 and BARD1β expression inIn vivo, the fibrotic lung tissues from humans and
mice showed an upregulation of FL BARD1 and BARD1β.
In vitro experiments confirmed the induction of FL
BARD1 and BARD1β on the transcriptional and protein
level in response to TGF-β to some extent. In vivo, how-
ever, their expression might also be driven by hypoxia.
Hypoxia is also a driver of miRNA expression in cancers
and could play an additive role on the regulation of
BARD1 expression, as BARD1 upregulation was observed
in response to hypoxia in vivo [16, 20]. This could be
reproduced in lung epithelial cells and fibroblast in culture
(Additional file 1: Figure S1).
Mechanism of action of FL BARD1 and its isoforms in
epithelial cells and fibroblasts
The intracellular functions of FL BARD1 and its
isoforms are not well understood. FL BARD1 is mostly
bound to BRCA1, and the BRCA1-BARD1 heterodimer
has E3 ubiquitin ligase activity [14, 15]. Several proteins
have been discovered that are ubiquitinated and de-
graded by the BRCA1-BARD1 ubiquitin ligase [14, 47],
including proteins that act in a signaling pathway from
genotoxic stress to repair [48]. Proteins that play a role
in cell cycle control, such as the centrosomal protein
gamma-tubulin, and Aurora kinases, have also been iden-
tified as targets of the BRCA1-BARD1 E3 ligase [22, 23].
The isoforms lacking the BRCA1 interaction domain still
retain the domain required for interaction with the ubi-
quitin ligase target protein. This is the case for BARD1β,
which lacks the RING domain, but contains the Aurora
kinase binding domain [23, 25]. BARD1β, by binding to
Aurora A and B, antagonizes their degradation. Aurora
kinases are required for progressing through cell cycle
checkpoints and for completion of cytokinesis [49]. In
non-transformed cells, Aurora kinases are synthesized
during S-phase and gradually degraded during mitosis, in
cancer cells their upregulation leads to uncontrolled pro-
gression through mitosis. This is also observed by FL
BARD1 repression and/or BARD1β upregulation [23, 25].
Thus, BARD1β antagonizes the function of FL BARD1
and BRCA1 and acts pro-proliferative by overridingepithelial cells and fibroblasts might contribute to lung fibrosis
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expression of BARD1β in fibrotic lung tissues is consistent
with the view that BARD1β might drive fibroblast prolifer-
ation by its binding to Aurora kinases. It is possible that
BARD1β also binds to other hitherto not identified target
proteins of the FL BARD1-BRCA1 ubiquitin ligase.
Fibrotic fibroblasts produce excessive collagen, and FL
BARD1 and/or other isoforms could be involved in lung
fibrosis due to their ubiquitin ligase function which
could contribute to the accumulation of collagen via
(de)regulation of collagen or other extra cellular matrix
protein production and/or turnover, which remains to
be investigated.Hypothesis and future directions
TGF-β has long been proposed as a key molecule central
to the pathogenesis of lung fibrosis [50]. However, it has
thus far proved to be an intractable target largely due to
the pleiotropic effects of this molecule, as well as its poten-
tial tumorigenic effects, and indirect approaches to modu-
late TGF-β signaling are considered [51, 52]. We suggest
that BARD1 might act as downstream activator of epithelial
cell apoptosis and fibroblast proliferation and therefore
might present a strong candidate target molecule for the
treatment of lung fibrosis and possibly other diseases in
which fibro-proliferation is a feature.Additional file
Additional file 1: Table S1. Table S1 shows a list of transcription
factors that bind to the BARD1 promoter sequence and are relevant to
TGF-β signaling. Figure S1. BARD1 is overexpressed in response to
hypoxia. Lung epithelial cells (human A549) and fibroblasts (mouse L929)
were cultured in normal condition or in hypoxia, and cell extracts were
prepared after 24 and 48 hours. Western Blot using anti-BARD1 BL
(mapping exon 4). In hypoxia conditions, both BARD1 FL and BARD1β
are upregulated in epithelial A549 cells. In fibroblasts L929, we can
observe an upregulation of BARD1β at 48h whereas FL BARD1 is only
weakly expressed. Figure S2. No staining observed in the absence of
primary antibody. IHC was performed on adjacent tissue sections from
NSIP patients without primary antibody (a-c) or with anti-BARD1 BL
antibody (d-f). Figure S3. BARD1 expression in non-malignant and
malignant cell lines. BARD1 expression is stronger in the murine
immortalized but non-tumorigenic cell line derived from alveolar type II
pneumocytes (E10) than in tumour cell lines (MLE12, murine tumorigenic
transformed lung epithelial cells and A549, human adenocarcinomic
alveolar basal epithelial cells). Figure S4. FL BARD1 and BARD1β
overexpression in A549 cells. (A) Exon structures of mRNAs of FL BARD1
and BARD1β. Arrows indicate position of forward and reverse primers
used for RT-PCR. (B) Epithelial cells (human lung cancer cells A549) were
transfected with FL BARD1 (FL and FL2) or BARD1β (β ) expressing
plasmids, or control plasmid (Co), and cell extracts were prepared after 48
hours. Reverse transcription and PCR was performed using primers from
human exon1 to 11 of FL BARD1 (ex1-ex11) and from human exon 1/4
junction (BARD1β -specific) to exon 11of BARD1β (ex1/4-ex11). GAPDH
PCR was performed as a control for cDNA quantity. Detailed Description
of Materials and Methods. (PDF 1516 kb)
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